A Phase 3 interventional study of CLS006 (Furosemide) Topical Gel and Vehicle Topical Gel in Cutaneous Common Warts, sponsored by Maruho Co., Ltd.. Completed at 30 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by Maruho Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.
Among the 59 studies in Warts with a site in United States, this one is the 4th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 32nd registered.
172 studies on the registry are indexed under Warts; 36 are open to participants now.
Browse Warts studies →7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Western Institute for Veterans Research · Sites in United States
Ages 18+
The Skin Center Dermatology Group · Sites in United States
Ages 4+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 13 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 484 is above the median of 70 across 156 interventional studies indexed under Warts.
Median enrollment 80 across the 58 interventional studies, 950 across the 1 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 59 have an industry lead sponsor. The 10 most frequent:
Maruho Co., Ltd. is the lead sponsor of 27 studies on the registry; none are open to participants now.
Maruho Co., Ltd. has 4 studies filed under Warts — fewer than ten, so there is no comparison to draw.
5 of the studies in Warts with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246590Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | 2026-11 |
| NCT07637734Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | 2027-05 |
| NCT07457918Phase 3Verrica Pharmaceuticals Inc.Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | 2027-11 |
| NCT07881952Verrica Pharmaceuticals Inc.Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | 2027-04 |
| NCT07806617Rush University Medical CenterIntralesional Gardasil-9 for the Treatment of Recalcitrant Warts | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 59 studies in Warts with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have 1 to 6 clearly identifiable common warts located on hands feet limbs, and/or trunk
Exclusion Criteria:
Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CLS006 (Furosemide) Topical Gel, 0.125%
Drug: CLS006 (Furosemide) Topical Gel
Vehicle Topical Gel
Drug: Vehicle Topical Gel
Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation.
Time frame: Week 18
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject
Time frame: Week 18
Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12.
Time frame: Week 12
The Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 12
Time frame: Week 12
Change From Baseline in Wart Size for Each Subject
Time frame: Week 18
Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk
| Milestone | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| Started | 246 | 238 |
| Subjects who had 1 wart | 118 | 117 |
| Subjects who had 2 warts | 56 | 53 |
| Subjects who had 3 warts | 24 | 24 |
| Subjects who had 4 warts | 21 | 12 |
| Subjects who had 5 warts | 12 | 11 |
| Subjects who had 6 warts | 15 | 21 |
| Completed | 229 | 214 |
| Not completed | 17 | 24 |
| Participants | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| Achieved complete clearance of all treated warts | 32 | 24 |
| Not achieved complete clearance of all treated warts | 197 | 190 |
| ratio of cleared warts | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject | 0.178 ± 0.3636 | 0.145 ± 0.3334 |
| Participants | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| Complete clearance of all treated warts | 21 | 14 |
| Not complete clearance of all treated warts | 208 | 200 |
| ratio of cleared warts | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| The Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 12 | 0.120 ± 0.3041 | 0.087 ± 0.2601 |
| mm | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| Change From Baseline in Wart Size for Each Subject | -2.5 ± 7.13 | -2.4 ± 6.64 |
Collected over 18 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CLS006 (Furosemide) | 0/246 (0%) | 0/246 (0%) | 9/246 (3.7%) |
| Vehicle | 0/238 (0%) | 0/238 (0%) | 9/238 (3.8%) |
| Event | CLS006 (Furosemide) | Vehicle |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/246 | 2/238 |
| SinusitisInfections and infestations | 1/246 | 4/238 |
| HeadacheNervous system disorders | 3/246 | 3/238 |
| Age, Continuous(years) | CLS006 (Furosemide) | Vehicle | Total |
|---|---|---|---|
| Mean | 28.6 ± 16.40 | 29.1 ± 16.57 | 28.8 ± 16.47 |
| Age, Customized(Participants) | CLS006 (Furosemide) | Vehicle | Total |
|---|---|---|---|
| >=2 to <12 | 43 | 37 | 80 |
| >=12 to <18 | 41 | 43 | 84 |
| >=18 to <65 | 158 | 154 | 312 |
| >=65 | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | CLS006 (Furosemide) | Vehicle | Total |
|---|---|---|---|
| Female | 105 | 101 | 206 |
| Male | 141 | 137 | 278 |
| Ethnicity (NIH/OMB)(Participants) | CLS006 (Furosemide) | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 39 | 78 |
| Not Hispanic or Latino | 205 | 199 | 404 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | CLS006 (Furosemide) | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Black or African American | 12 | 10 | 22 |
| White | 226 | 221 | 447 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 3 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2017, a primary completion of Apr 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2023, 5 years 4 months after primary completion. A results delay was requested in Apr 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide